Over recent decades, obesity has grown into a global health crisis where 38% of U.S. adults and more than 17% of children are currently obese. A 2015 study revealed statistics that are even more alarming: more than 600 million adults and 100 million children worldwide are considered obese.
Pharmacists practicing at the top of their licenses is something Ed Vess, R.Ph., has long advocated. QS/1’s senior manager of pharmacy professional affairs wants pharmacists to use their education to provide clinical patient care and claim their place as reimbursed members of the healthcare team.
It may seem like an extra burden to join and spend money on yet another professional organization, but the benefits of doing so are immense.
As a 36-year QS/1 customer, the Heart of Texas Community Health Center, known locally as Waco Family Health Center, has relied on pharmacy solutions that fit its unique setup and can be customized as the need arises.
When you purchase our pharmacy software solutions, you become part of our community. As a team, we work together to guarantee you get the most out of your software while providing your pharmacy with the resources needed to be successful, ensuring your voice is heard, and continuously improving our services to aid you.
Of all the caregivers a patient encounters, community pharmacists are often the most accessible. There is increasing focus on how their availability and clinical know-how can be used to create better outcomes for patients, particularly the high-risk and chronically ill.
A new member of the J M Smith corporate family, Mevesi is now part of the Integra product suite. Already integrated with QS/1’s NRx and Integra’s PrimeCare, its platforms include Business Intelligence, Pharmacy Edge, and Transitions of Care geared to the pharmacy-hospital relationship.
Remember wondering: When will I ever use pharmacokinetic/pharmacodynamic (PK/PD) modeling? Recall constant musing over: How will I keep my patients loyal to me? Or, how can I have a new revenue stream that ties into my professional license? Well, enter personalized and precision pharmacotherapy.
The year 2017 and early 2018 have been quite a whirlwind for the pharmacy industry. In terms of market performance, dollar growth remains in the low, single digits, following the Hepatitis C bubble in 2014 and 2015.
Policymakers in Washington, DC, are exploring reforms to lower drug costs that could mark the most significant changes in decades to how the federal government pays for drugs.